# EDGAR Filing Document

**Accession Number:** 0001029142
**File Stem:** 0001193125-26-043626
**Filing Date:** 2026-2
**Character Count:** 7872
**Document Hash:** 8df6cc0deb46c7ba1fd8fe9d410fb103
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-043626.hdr.sgml**: 20260210

**ACCESSION NUMBER**: 0001193125-26-043626

**CONFORMED SUBMISSION TYPE**: SC 14D9/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260210

**DATE AS OF CHANGE**: 20260210

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DYNAVAX TECHNOLOGIES CORP
- **CENTRAL INDEX KEY:** 0001029142
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 330728374
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 14D9/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-80035
- **FILM NUMBER:** 26613400

**BUSINESS ADDRESS:**
- **STREET 1:** 2100 POWELL STREET
- **STREET 2:** SUITE 720
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
- **BUSINESS PHONE:** 5108485100

**MAIL ADDRESS:**
- **STREET 1:** 2100 POWELL STREET
- **STREET 2:** SUITE 720
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DYNAVAX TECHNOLOGIES CORP
- **CENTRAL INDEX KEY:** 0001029142
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 330728374
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 14D9/A

**BUSINESS ADDRESS:**
- **STREET 1:** 2100 POWELL STREET
- **STREET 2:** SUITE 720
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
- **BUSINESS PHONE:** 5108485100

**MAIL ADDRESS:**
- **STREET 1:** 2100 POWELL STREET
- **STREET 2:** SUITE 720
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE 14D-9** 

**(Amendment No. 4)** 

**SOLICITATION/RECOMMENDATION STATEMENT** 

**UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934** 

## Dynavax Technologies Corporation
**(Name of Subject Company)** 

**(Name of Person(s) Filing Statement)** 

**Common Stock, $0.001 par value** 

**(Title of Class of Securities)** 

**268158201** 

**(CUSIP Number of Class of Securities)** 

**Ryan Spencer** 

**Chief Executive Officer** 

**Dynavax Technologies Corporation** 

**2100 Powell Street, Suite 720** 

**Emeryville, California 94608** 

**(510) 848-5100** 

***With copies to:***

**Barbara L. Borden** 

**Bill Roegge** 

**Steven M. Przesmicki** 

**Cooley LLP** 

**10265 Science Center Drive** 

**San Diego, California 92121** 

**(858) 550-6000** 

**(Name, address, and telephone numbers of person authorized to receive notices and communications** 

**on behalf of the persons filing statement)** 

☐ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

------

This Amendment No. 4 (this "Amendment") to Schedule 14D-9 amends and supplements the Schedule 14D-9 previously filed by Dynavax Technologies Corporation, a Delaware corporation (the "Company"), with the Securities and Exchange Commission (the "SEC") on January 12, 2026 (as amended or supplemented from time to time, the "Schedule 14D-9"), with respect tender offer by Samba Merger Sub, Inc., a Delaware corporation ("Purchaser") and an indirect wholly owned subsidiary of Sanofi, a French société anonyme ("Parent"), to purchase any and all of the issued and outstanding Shares of the Company for $15.50 per Share in cash, without interest, subject to any applicable withholding taxes, upon the terms and subject to the conditions set forth in that certain Offer to Purchase dated January 12, 2026 (together with any amendments or supplements thereto, the "Offer to Purchase"), and in the related Letter of Transmittal (together with any amendments or supplements thereto, the "Letter of Transmittal," which, together with the Offer to Purchase, constitutes the "Offer"). The Offer is described in a Tender Offer Statement on Schedule TO (as amended or supplemented from time to time, the "Schedule TO") filed by Parent and Purchaser with the SEC on January 12, 2026. The Offer to Purchase and the Letter of Transmittal have been filed as Exhibits (a)(1)(A) and (a)(1)(B) to the Schedule 14D-9, respectively, and are incorporated therein by reference.

Capitalized terms used in this Amendment but not defined herein shall have the respective meaning given to such terms in the Schedule 14D-9. Except to the extent specifically amended or supplemented as provided in this Amendment, the information set forth in the Schedule 14D-9 remains unchanged.

**Item 8. Additional Information.** 

Item 8 of the Schedule 14D-9 is hereby amended and supplemented by adding the following new section before the section entitled "*Item 8. Additional Information — (h) Cautionary Note Regarding Forward-Looking Statements*" on page 60:

**"Final Results of the Offer and Completion of the Merger** 

The Offer and withdrawal rights expired as scheduled at one minute following 11:59 P.M., Eastern Time, on February 9, 2026 (such date and time, the "Expiration Time"), and the Offer was not extended. Purchaser was advised by Continental Stock Transfer & Trust Company, which is the depository and paying agent for the Offer, that, as of the Expiration Time, a total of 84,680,752 Shares had been validly tendered into and not validly withdrawn pursuant to the Offer, which Shares represented approximately 73.92% of the aggregate number of Shares then outstanding. Accordingly, the number of Shares validly tendered and not validly withdrawn pursuant to the Offer satisfied the Minimum Condition.

Purchaser has irrevocably accepted for payment, and has stated it will promptly pay for, all Shares validly tendered and not validly withdrawn pursuant to the Offer.

As a result of its acceptance of the Shares tendered pursuant to the Offer and in accordance with Section 251(h) of the DGCL, Purchaser owns a number of Shares that is greater than the percentage of Shares that would be required to adopt the Merger Agreement by a vote of the stockholders of the Company. Pursuant to Section 251(h) of the DGCL, subject to the satisfaction of the remaining conditions set forth in the Merger Agreement, Parent and Purchaser intend to complete the acquisition of the Company through the Merger, as promptly as practicable and without a meeting of stockholders of the Company. At the Effective Time and as a result of the Merger, each Share issued and outstanding immediately prior to the Effective Time (other than (i) Shares held in the treasury of the Company (other than, in each case, Shares that are held in a fiduciary or agency capacity and are beneficially owned by third parties), (ii) Shares owned by Parent, the Company or any of their respective direct or indirect wholly owned subsidiaries (other than Purchaser), (iii) Shares irrevocably accepted by Purchaser for purchase in the Offer and (iv) Shares held by holders who are entitled to demand and properly exercise and perfect their respective demands for appraisal of such Shares in accordance with Section 262 of the DGCL) will be cancelled and converted into the right to receive the Offer Consideration, without interest and subject to any withholding of taxes required by applicable legal requirements.

Following the Merger, the Shares will no longer be listed on the Nasdaq Global Select Market and will be deregistered under the Exchange Act."

------

**SIGNATURE** 

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---

| | | |
|:---|:---|:---|
| Dated: February 10, 2026 | Dynavax Technologies Corporation | Dynavax Technologies Corporation |
|  | By: | /s/ Ryan Spencer |
|  | Name: | Ryan Spencer |
|  | Title: | Chief Executive Officer |

---